2009-09-23 22:12:04 -

E-18 Corp. (OTCBB: ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces completion of the US patent filing for the Protectus Safety Dental Syringe, broadening the company’s market opportunities to include the multi-billion dollar dental syringe market.

The new Protectus Safety Dental Syringe device will be fully compliant with all OSHA regulations under the federal Needlestick Safety Act while meeting the clinical needs of dentists throughout the United States. The patent filing immediately gives Protectus Medical design and utility patent-pending status.

“Complementing our revolutionary, self-sheathing, hypodermic safety syringe, the Protectus Safety Dental Syringe will provide significant accidental needlestick protection for dental healthcare providers,” said Dr. John Salstrom, President and CEO of

Protectus Medical Devices. “What makes this dental syringe announcement so timely for shareholders and investors is not just the fact that we are pursuing substantial new growth opportunities in the multi-billion dollar dental syringe market, but due to their increased complexity, dental syringes are typically a higher margin business as well.”

The Protectus Safety Dental Syringe incorporates a unique non-uniform, flattened helix design, known as the Helix Actuator Spring, that allows the spring to fully collapse and expose the entire needle, while simultaneously supplying sufficient force for the self-sheathing action to be fully effective at any stage of spring contraction.

Dr. Salstrom added, “By employing truly self-sheathing technology, the Protectus Dental Syringe could significantly reduce or obviate needlestick injuries that affect dentists and other dental healthcare providers, while also using design elements that keep costs competitive and make injections during dental visits as safe as possible.”

Developed by Protectus Medical Devices, the Protectus Dental Syringe has the potential to revolutionize this segment of the healthcare system as the only safety dental syringe in the world that self-sheaths and meets every requirement of the OSHA mandates passed by the U.S. Federal Government. For more information about Protectus Medical Devices, please visit: www.protectusmedical.com :



About E-18 Corp.

E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim.
Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com : .


Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.



Company Contact:E-18 Corp.John Salstrom, President
and CEO1-800-778-8438 moreinfo@protectusmedical.com : mailto:moreinfo@protectusmedical.com orFinancial
Communications Contact:Trilogy Capital PartnersDarren

Minton, Vice PresidentToll-free: 800-592-6067 info@trilogy-capital.com : mailto:info@trilogy-capital.com